Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects

References

• Wang LY, Sun MP, Zhang XC, Suo LD, Xu RH, Zou YJ, Zuo LB, Qi H. Safety and immunogenicity of two freeze-dried vero cell rabies vaccines for human use in post-exposure prophylaxis. Vaccine 2011; 29:2679-81; PMID:21296694; https://doi.org/10.1016/j.vaccine.2011.01.053
   PubMed Web of Science ®Google Scholar
• WHO Expert consultation on rabies: first report. WHO technical report series, 931. Geneva Switzerland: World Health Organization 2005.
   Google Scholar
• National Health and Family Planning Commission of the People's Republic of China. Available at: http://www.nhfpc.gov.cn/.
   Google Scholar
• Yu J, Li H, Tang Q, Rayner S, Han N, Guo Z, Liu H, Adams J, Fang W, Tao X, et al. The spatial and temporal dynamics of rabies in China. PLos Negl Trop Dis 2012; 6:e1640; PMID:22563518; https://doi.org/10.1371/journal.pntd.0001640
   PubMed Web of Science ®Google Scholar
• Si H, Guo ZM, Hao YT, Liu YG, Zhang DM, Rao SQ, Lu JH. Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province. BMC Infect Dis 2008; 8:113; PMID:18717989; https://doi.org/10.1186/1471-2334-8-113
   PubMed Web of Science ®Google Scholar
• WHO Expert Committee on Rabies. Guide for post-exposure treatment. Eighth report. WHO technical report 824. Geneva Switzerland: World Health Organization 1992.
   Google Scholar
• Ma J, Wang H, Li J, Chang L, Xie Y, Liu Z, Zhao Y, Malerczyk C. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the zagreb regimen (2-1-1) compared with the essen regimen in chinese adults. Hum Vaccin Immunother 2014; 10:2805-12; PMID:25483635; https://doi.org/10.4161/21645515.2014.972773
   PubMed Web of Science ®Google Scholar
• Mahendra BJ, Narayana DA, Agarkhedkar S, Ravish HS, Harish BR, Agarkhedkar S, Madhusudana SN, Belludi A, Ahmed K, Jonnalagedda R, et al. Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine(PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen). Hum Vaccin Immunother 2015;11:428-34; PMID:25692792; https://doi.org/10.4161/21645515.2014.995059
   PubMed Web of Science ®Google Scholar
• Li R, Li Y, Wen S, Wen H, Nong Y, Mo Z, Xie F, Pellegrini M. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years:a randomized open-label study. Hum Vaccin Immunother 2015; 11:435-42; PMID:25692350; https://doi.org/10.4161/21645515.2014.994460
   PubMed Web of Science ®Google Scholar
• Wang CL, Zhang XW, Yu YX. Study on the Compliance and economic cost of rabies vaccination. Zhong guo Yi Miao He Mian Yi 2010; 16:254-7; PMID:20726270
   PubMedGoogle Scholar
• Hu Q, Liu MQ, Zhu ZG, Zhu ZR, Lu S. Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China. Hum Vaccin Immunother 2014;10:1645-9; PMID:24632727; https://doi.org/10.4161/hv.28420
   PubMed Web of Science ®Google Scholar
• Liu H, Huang G, Tang Q, Li J, Cao S, Fu C, Cao Q, Liu B, Pan H, Wang M. The immunogenicity and safety of vaccination with purified vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Hum Vaccin 2011; 7:220-4; PMID:21311216; https://doi.org/10.4161/hv.7.2.14003
   PubMed Web of Science ®Google Scholar
• Vodopija I, Sureau P, Lafon M, Baklaic Z, Ljubicić M, Svjetlicić M, Smerdel S. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine 1986; 4:245-8; PMID:3541428; https://doi.org/10.1016/0264-410X(86)90138-6
   PubMed Web of Science ®Google Scholar
• Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett SM, Levis R, Meltzer MI, Schaffner W, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010; 59:1-9; PMID:20300058
   PubMedGoogle Scholar
• Chutivongse S, Wilde H, Fishbein DB, Baer GM, Hemachudha T. One-year study of the 2-1-1 intramuscular post exposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 1991; 9:573-6; PMID:1771970; https://doi.org/10.1016/0264-410X(91)90244-Z
   PubMed Web of Science ®Google Scholar
• Colnot F, Sureau P, Alexandre JL, Arnaudo JP, Hesse JY, Jeanmaire H. Post-exposure antirabies vaccination. Early serological response to vaccine cultivated on VERO cells using a reduced 2-1-1 schedule. Presse Med 1994; 23:1609-12; PMID:7831241
   PubMed Web of Science ®Google Scholar
• Vodopija I, Baklaic Z, Vodopija R. Rabipur: a reliable vaccine for rabies protection. Vaccine 1999; 17:1739-41; PMID:10194832; https://doi.org/10.1016/S0264-410X(98)00427-7
   PubMed Web of Science ®Google Scholar
• Vodopija I, Sureau P, Smerdel S, Lafon M, Baklaić Z, Ljubicić M, Svjetlicić M. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine 1988; 6:283-6; PMID:3420976; https://doi.org/10.1016/0264-410X(88)90225-3
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang X, Song Q, Tang K. Promising rabies vaccine for post exposure prophylaxis in developing countries, a purified Vero cell vaccine produced in China. Clin Vaccine Immunol 2010; 17:688-90; PMID:20147495; https://doi.org/10.1128/CVI.00433-09
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu Z, Wang C. Persistence of rabies antibody 5 years after post exposure prophylaxis with Vero Cell anti-rabies vaccine and antibody response to a single booster dose. Clin Vaccine Immunol 2011; 18:1477-9; PMID:21752947; https://doi.org/10.1128/CVI.05090-11
   PubMed Web of Science ®Google Scholar
• Yu P, Huang Y, Zhang Y, Tang Q, Liang G. Production and evaluation of a chromatographically purified Vero cell rabies vaccine (PVRV) in China using microcarrier technology. Hum Vaccin Immunother 2012; 8:1230-5; PMID:22894963; https://doi.org/10.4161/hv.20985
   PubMed Web of Science ®Google Scholar
• Huang G, Liu H, Cao Q, Liu B, Pan H, Fu C. Safety of post-exposure rabies prophylaxis during pregnancy: A follow-up study from Guangzhou, China. Hum Vaccin Immunother 2013; 9:177-83; PMID:23442589; https://doi.org/10.4161/hv.22377
   PubMed Web of Science ®Google Scholar
• Huang G, Liu H, Tang Q, Yu P, Shen X, Zhang Y, Liu X, Cao Q, Fu C, Liu B, et al. Making rabies prophylaxis more economical:immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers. Hum Vaccin Immunother 2014; 10:114-9; PMID:24008819; https://doi.org/10.4161/hv.26264
   PubMed Web of Science ®Google Scholar
• Fang Y, Chen L, Liu MQ, Zhu ZG, Zhu ZR, Hu Q. Comparison of safety and immunogenicity of PVRV and PCECV immunized in patients with WHO category II animal exposure: a study based on different age groups.
   Google Scholar
• Zhang X, Zhu Z, Wang C. Persistence of Rabies Antibody 5 Years after Postexposure Prophylaxis with Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose. Clin Vaccine Immunol 2011; 18:1477-9; PMID:21752947; https://doi.org/10.1128/CVI.05090-11
   PubMed Web of Science ®Google Scholar
• Zalan E, Wilson C, Pukitis D. A microtest for the quantitation of rabies virus neutralizing antibodies. J Biol Stand 1979; 7:213-20; PMID:387798; https://doi.org/10.1016/S0092-1157(79)80024-4
   PubMedGoogle Scholar
• World Health Organization. Rabies vaccine: WHO position paper. Weekly Epidemiol Rec 2010;85:309-20.
   Google Scholar
• World Health Organization. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser 2013:1-139, back cover.
   Google Scholar
• China Food and Drug Administration. The standard guidelines for adverse reactions grading of vaccine clinical trials, Oct 14, 2005. Available at: http://www.sda.gov.cn/WS01/CL0844/9350_5.html.
   Google Scholar
• Tao XY, Tang Q, Li H, Mo ZJ, Zhang H, Wang DM, Zhang Q, Song M, Velasco-Villa A, Wu X, et al. Molecular epidemiology of rabies in Southern People's Republic of China. Emerg Infect Dis 2009; 15:1192-8; PMID:19751579; https://doi.org/10.3201/eid1508.081551
   PubMed Web of Science ®Google Scholar
• Lang SL, Tao XY, Guo ZY, Tang Q, Li H, Yin CP, Li Y, Liang GD. Molecular characterization of viral G gene in emerging and re-emerging areas of rabies in China, 2007 to 2011. Virol Sin 2012; 27:194-203; PMID:22684474; https://doi.org/10.1007/s12250-012-3248-7
   PubMedGoogle Scholar